Key Points
- Amphastar CFO William Peters sold 8,180 shares for approximately $183,886 at an average price of $22.48, reducing his holdings by 4.52% to 172,846 shares. The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan.
- The company reported quarterly EPS of $0.91, exceeding analyst expectations of $0.62, while revenue of $183.9 million also topped estimates. Shares opened at $20.42 and were recently trading near the lower half of their 52-week range.
- Analyst sentiment remains cautious, with a consensus rating of “Reduce” and an average price target of $22.00. Several firms recently cut their price targets, although institutional investors collectively own about 65.1% of the stock.
Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Get Free Report) CFO William Peters sold 8,180 shares of Amphastar Pharmaceuticals stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $22.48, for a total value of $183,886.40. Following the completion of the transaction, the chief financial officer owned 172,846 shares of the company's stock, valued at approximately $3,885,578.08. This trade represents a 4.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Amphastar Pharmaceuticals Trading Up 0.5%
Shares of AMPH opened at $20.42 on Wednesday. Amphastar Pharmaceuticals, Inc. has a twelve month low of $16.65 and a twelve month high of $31.26. The company has a market cap of $868.67 million, a P/E ratio of 12.08, a P/E/G ratio of 4.29 and a beta of 0.89. The company has a current ratio of 2.40, a quick ratio of 1.71 and a debt-to-equity ratio of 0.79. The company's fifty day simple moving average is $19.74 and its 200-day simple moving average is $21.28.
Amphastar Pharmaceuticals (NASDAQ:AMPH - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.62 by $0.29. Amphastar Pharmaceuticals had a return on equity of 14.98% and a net margin of 10.76%.The firm had revenue of $183.90 million during the quarter, compared to analyst estimates of $179.92 million. As a group, analysts expect that Amphastar Pharmaceuticals, Inc. will post 2.25 EPS for the current year.
Institutional Investors Weigh In On Amphastar Pharmaceuticals
A number of large investors have recently modified their holdings of the business. Rice Hall James & Associates LLC grew its position in Amphastar Pharmaceuticals by 54.6% during the 1st quarter. Rice Hall James & Associates LLC now owns 187,348 shares of the company's stock worth $3,670,000 after purchasing an additional 66,172 shares during the last quarter. Denali Advisors LLC raised its stake in Amphastar Pharmaceuticals by 56.9% in the 4th quarter. Denali Advisors LLC now owns 211,765 shares of the company's stock worth $5,671,000 after acquiring an additional 76,765 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Amphastar Pharmaceuticals by 12.7% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,027,947 shares of the company's stock worth $39,726,000 after acquiring an additional 228,262 shares during the period. Pacer Advisors Inc. lifted its position in Amphastar Pharmaceuticals by 47.1% during the 1st quarter. Pacer Advisors Inc. now owns 261,483 shares of the company's stock worth $5,122,000 after acquiring an additional 83,739 shares during the period. Finally, Cibc World Market Inc. acquired a new position in shares of Amphastar Pharmaceuticals in the fourth quarter valued at about $1,666,000. Hedge funds and other institutional investors own 65.09% of the company's stock.
Analyst Upgrades and Downgrades
Several equities research analysts have recently weighed in on the stock. Piper Sandler lowered their price target on shares of Amphastar Pharmaceuticals from $21.00 to $20.00 and set a "neutral" rating for the company in a research report on Friday, August 7th. Needham & Company LLC reaffirmed a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Friday, May 8th. Barclays reduced their price target on Amphastar Pharmaceuticals from $23.00 to $20.00 and set an "equal weight" rating for the company in a research report on Wednesday, June 3rd. Wall Street Zen upgraded shares of Amphastar Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Saturday. Finally, Bank of America restated an "underperform" rating and issued a $20.00 price target (down from $25.00) on shares of Amphastar Pharmaceuticals in a report on Monday, June 29th. Six investment analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, Amphastar Pharmaceuticals has a consensus rating of "Reduce" and an average price target of $22.00.
View Our Latest Stock Report on Amphastar Pharmaceuticals
About Amphastar Pharmaceuticals
(
Get Free Report)
Amphastar Pharmaceuticals, Inc is a specialty pharmaceutical company headquartered in Rancho Cucamonga, California. Founded in 2004, Amphastar focuses on the development, manufacturing and commercialization of injectable and inhalation products. The company's manufacturing facilities in California produce both generic and proprietary formulations designed to address urgent and chronic medical conditions.
Amphastar's portfolio includes a range of injectable generics such as epinephrine, naloxone and lidocaine, serving hospital, emergency medical and retail pharmacy channels.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
